Status:

RECRUITING

Links Between Cognitive Deficits During Normal or Pathological Aging and Slow Waves Measured in EEG

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Conditions:

Aging

Alzheimer Disease

Eligibility:

All Genders

18-85 years

Phase:

NA

Brief Summary

With age, memory processes (encoding, consolidation and retrieval) as well as daytime vigilance are altered. Sleep is also impaired in older adults, notably slow waves that are known to play a key rol...

Detailed Description

Introduction Aging is accompanied by cognitive decline, particularly affecting memory functions. Additionally, both the quantity and quality of sleep decrease with advancing age, specifically altering...

Eligibility Criteria

Inclusion

  • Common Inclusion Criteria for All Three Groups:
  • Male or female Signed informed consent Affiliated with a social security system Native French speakers Completed at least 7 years of schooling (minimum 9th grade level)
  • Specific Inclusion Criteria for Each Group:
  • Patients:
  • Age: 60 to 85 years Prodromal stage of Alzheimer's disease diagnosed according to international diagnostic criteria, characterized by a clinical phenotype of progressive amnesic syndrome of the hippocampal type, associated with biological markers of Alzheimer's disease from lumbar puncture (Aβ \< 600 pg/mL and ptau \> 60 pg/mL)
  • Cognitively Healthy Seniors:
  • Age: 60 to 85 years Age and sex matched with the Patients group "Cognitively healthy" status defined by a score of ≥ 26 on the MMSE (Mini-Mental State Examination), a score of ≥ 16 on the BREF (Batterie Rapide d'Efficience Frontale), and a score of ≥ 8 on the 5-word test
  • Young Adults:
  • Age: 18 to 35 years Sex matched with the Patients group "Cognitively healthy" status defined by a score of ≥ 26 on the MMSE (Mini-Mental State Examination), a score of ≥ 16 on the BREF (Batterie Rapide d'Efficience Frontale), and a score of ≥ 8 on the 5-word test

Exclusion

    Key Trial Info

    Start Date :

    April 24 2025

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    April 1 2027

    Estimated Enrollment :

    90 Patients enrolled

    Trial Details

    Trial ID

    NCT06501495

    Start Date

    April 24 2025

    End Date

    April 1 2027

    Last Update

    May 1 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Maladies du Sommeil

    Paris, France, 75013